How are IBRX strangle max profit and max loss calculated?

Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the IBRX strangle priced from the August 14, 2026 end-of-day chain at a 30-day expiry (ATM IV 71.40%), the computed maximum profit is unbounded per contract and the computed maximum loss is -$81.50 per contract. Live intraday quotes will differ as the chain moves through the trading session.

What is the breakeven for a IBRX strangle?

The breakeven for the IBRX strangle priced on this page is roughly $6.19 and $8.82 at expiration, derived from the August 14, 2026 end-of-day chain's premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The IBRX market-implied 1-standard-deviation expected move in the same options snapshot is approximately 20.47%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.

How does current IBRX implied volatility affect this strangle?

IBRX ATM IV is at 71.40% with IV rank near 27.86%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.

IBRX Strangle Strategy

IBRX (ImmunityBio, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.

ImmunityBio, Inc. is a clinical-stage biotechnology firm, founded in 2014 and based in San Diego, California. The company is focused on developing groundbreaking therapies and vaccines designed to treat a wide array of cancers and infectious diseases. Its innovative approach relies on a comprehensive suite of immunotherapy and cell therapy platforms. These advanced technologies include novel antibody-cytokine fusion proteins, synthetically engineered immunomodulators, cutting-edge vaccine technologies, natural killer (NK) cell therapies, and strategies that harness the adaptive (T-cell) immune system. ImmunityBio currently has several therapeutic candidates in advanced clinical development, with agents undergoing Phase II or III trials. These investigational treatments are aimed at various liquid and solid tumors, such as bladder, pancreatic, and lung cancers, as well as significant infectious pathogens including SARS-CoV-2 and HIV.

IBRX (ImmunityBio, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $8.11B, a beta of 0.13 versus the broader market, a 52-week range of 1.95-12.43, average daily share volume of 13.0M, a public-listing history dating back to 2015, approximately 688 full-time employees. These structural characteristics shape how IBRX stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.

A beta of 0.13 indicates IBRX has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure.

What is a strangle on IBRX?

A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.

IBRX snapshot

As of August 14, 2026, spot at $7.54, ATM IV 71.40%, IV rank 27.86%, expected move 20.47%. The strangle on IBRX below is built from the August 14, 2026 end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 28-day expiry.

Why this strangle structure on IBRX specifically: IBRX IV at 71.40% is on the cheap side of its 1-year range, which favors premium-buying structures like a IBRX strangle, with a market-implied 1-standard-deviation move of approximately 20.47% (roughly $1.54 on the underlying). The 28-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated IBRX expiries trade a higher absolute premium for lower per-day decay. Position sizing on IBRX should anchor to the underlying notional of $7.54 per share and to the trader's directional view on IBRX stock.

IBRX strangle setup

The IBRX strangle below is built from the August 14, 2026 end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With IBRX at $7.54 on that close, the first option leg uses a $8.00 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed IBRX chain at a 28-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 IBRX shares for the stock leg in covered calls and collars).

Action	Type	Strike / Basis	Premium (est)
Buy 1	Call	$8.00	$0.49
Buy 1	Put	$7.00	$0.33

IBRX strangle risk and reward

Net Premium / Debit: -$81.50
Max Profit (per contract): Unbounded
Max Loss (per contract): -$81.50
Breakeven(s): $6.19, $8.82
Risk / Reward Ratio: Unbounded

Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.

IBRX strangle payoff curve

Modeled P&L at expiration across a range of underlying prices for the strangle on IBRX. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.

P&L at expiration across the modeled underlying-price range. Green shading marks profitable regions, red shading marks loss regions. Dotted purple verticals mark breakevens; the solid dark vertical marks current spot.

Underlying Price	% From Spot	P&L at Expiration
$0.01	-99.9%	+$617.50
$1.68	-77.8%	+$450.90
$3.34	-55.7%	+$284.29
$5.01	-33.6%	+$117.69
$6.67	-11.5%	-$48.91
$8.34	+10.6%	-$47.48
$10.01	+32.7%	+$119.12
$11.67	+54.8%	+$285.72
$13.34	+76.9%	+$452.32
$15.00	+99.0%	+$618.93

When traders use strangle on IBRX

Strangles on IBRX are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the IBRX chain.

IBRX thesis for this strangle

The market-implied 1-standard-deviation range for IBRX extends from approximately $6.00 on the downside to $9.08 on the upside. A IBRX long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current IBRX IV rank near 27.86% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on IBRX at 71.40%. As a Healthcare name, IBRX options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to IBRX-specific events.

IBRX strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. IBRX positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move IBRX alongside the broader basket even when IBRX-specific fundamentals are unchanged. Always rebuild the position from current IBRX chain quotes before placing a trade.

Frequently asked questions

What is a strangle on IBRX?: A strangle on IBRX is the strangle strategy applied to IBRX (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With IBRX stock at $7.54 on the August 14, 2026 close, the strikes shown on this page are snapped to the nearest listed IBRX chain strike and the premiums come straight from that session's bid/ask midpoint.
How are IBRX strangle max profit and max loss calculated?: Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the IBRX strangle priced from the August 14, 2026 end-of-day chain at a 30-day expiry (ATM IV 71.40%), the computed maximum profit is unbounded per contract and the computed maximum loss is -$81.50 per contract. Live intraday quotes will differ as the chain moves through the trading session.
What is the breakeven for a IBRX strangle?: The breakeven for the IBRX strangle priced on this page is roughly $6.19 and $8.82 at expiration, derived from the August 14, 2026 end-of-day chain's premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The IBRX market-implied 1-standard-deviation expected move in the same options snapshot is approximately 20.47%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
When should you consider a strangle on IBRX?: Strangles on IBRX are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the IBRX chain.
How does current IBRX implied volatility affect this strangle?: IBRX ATM IV is at 71.40% with IV rank near 27.86%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.